InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (5 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
5
T+90 hit rate
50%
T+90 mean return
-7.0%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Higgins John l, Chairman & CEO. Officer active across 3 companies, notably Ligand Pharmaceuticals INC. In total, 46 filings have been recorded. Split: 4 buys · 5 sells. Total volume traded: €2.4m. Activity tracked since 30 June 2021. The latest transaction was filed on 6 November 2025 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Higgins John l
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations46 total
13,172 sharesCommon StockSEC:0001208906-26-000003:0
36,223 shares@ US$1.416.3% of flowCommon StockSEC:0001208906-25-000011:0
Canonical exit: 4 Feb 2026 (T+90)
1,640 shares0Common StockSEC:0000914190-25-000021:0
5,040 shares@ US$21.847.5% of flowCommon StockSEC:0001437749-25-026007:0
20,000 sharesCommon StockSEC:0001208906-25-000004:0
65,000 shares@ US$1.4412.8% of flowCommon StockSEC:0001628280-25-025224:0
Canonical exit: 10 Aug 2025 (T+90)
12,000 shares@ US$21.8419.9% of flowCommon StockSEC:0001062993-25-008474:0
4,000 shares@ US$2.281.3% of flowCommon StockSEC:0001846253-25-000030:0
Canonical exit: 19 Jun 2025 (T+90)
125,750 shares@ US$2.3541.2% of flowCommon StockSEC:0001846253-25-000028:0
Canonical exit: 18 Jun 2025 (T+90)
13,172 sharesCommon StockSEC:0001846253-25-000008:0
1,462 shares0Common StockSEC:0001062993-24-018031:0
6,000 shares@ US$22.9510.6% of flowCommon StockSEC:0001062993-24-016642:0
6,000 shares@ US$22.9510.9% of flowCommon StockSEC:0001062993-24-013645:0
20,000 sharesCommon StockSEC:0001846253-24-000054:0
4,000 shares@ US$22.957.3% of flowCommon StockSEC:0001062993-24-010446:0
2,427,861 sharesCommon StockSEC:0001846253-24-000016:0
13,173 sharesCommon StockSEC:0002001011-24-000011:0
1,625 shares0Common StockSEC:0001062993-23-019850:0
25,914 shares@ US$3.6613.6% of flowCommon StockSEC:0001846253-23-000087:0
9,000 shares@ US$3.684.7% of flowCommon StockSEC:0001846253-23-000078:0
1,000 shares@ US$3.680.5% of flowCommon StockSEC:0001846253-23-000076:0
50,000 shares@ US$3.6826.0% of flowCommon StockSEC:0001846253-23-000074:0
16,000 shares@ US$21.8527.1% of flowCommon StockSEC:0001062993-23-009932:0
39,517 shares0Common StockSEC:0001846253-23-000011:0
5,289 shares@ US$66.298.0% of flowCommon StockSEC:0000899243-22-039580:0
25 of 46 declarations
About Higgins John l
HIGGINS JOHN L is Président-Directeur Général and a director of Ligand Pharmaceuticals INC, OmniAb, Inc. and BIO-TECHNE Corp. Across 46 total filings, the 46 sampled filings run from 2016-02-16 to 2026-01-30, with EUR 408000 in buys and EUR 2023694 in sells, and the most frequent transaction nature is Levée d'options.
